5-lipoxygenase-activating protein (FLAP) inhibitors

A compound having the structure of Formula (A):

• wherein,
• Y is substituted or unsubstituted heterocyclalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclic aryl
• R6 is H, L2-(substituted or unsubstituted alkyl), L2-(substituted or unsubstituted cycloalkyl), L2-(substituted or unsubstituted alkenyl), L2-(substituted or unsubstituted cycloalkenyl), L2-(substituted or unsubstituted heterocycloalkyl), L2-(substituted or unsubstituted heteroaryl), or L2-(substituted or unsubstituted carbocyclic aryl), where L2 is a bond, O, S, —S(═O), —S(═O)2, C(O), -(substituted or unsubstituted C1-C6 alkyl), or -(substituted or unsubstituted C2-C6 alkenyl);
• R7 is L3-X-L4-G, wherein,
• X is a bond, O, —C(═O), S, —S(═O), —S(═O)2, —NH, —NR8, —NHC(O), —C(O)NH, —NR8C(O), —C(O)NR8, —S(═O)2NH, —NHS(═O)2, —S(═O)2NR8—, —NR8S(═O)2, —OC(O)NH—, —NHC(O)O—, —OC(O)NR8—, —NR8C(O)O—, —CH═NO—, —ON═CH—, —NR9C(O)NR9—, heteroaryl, aryl, —NR9C(═NR10)NR9—, —NR9C(═NR10)—, —C(═NR10)NR9—, —OC(═NR10)—, or —C(═NR10)O—;
• L3 is a bond, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocylic aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl;
• L4 is a bond, optionally substituted or unsubstituted alkyl, optionally substituted or unsubstituted cycloalkyl, optionally substituted or unsubstituted alkenyl, optionally substituted or unsubstituted alkynyl;
• G is H, —CO2H, tetrazolyl, —NHS(═O)2R8, S(═O)2N(R9), OH, —OR8, —C(═O)CF3, —C(O)NHS(═O)2R8, —S(═O)2NHC(O)R8, CN, N(R9)2, —C(═NR10)N(R8)2, —NR9C(═NR10)N(R9)2, —NR9C(═CHR10)N(R9)2, —CO2R8, —C(O)R8, —CON(R9)2, —SR8,—S(═O)R9, —S(═O)2R8, -L5-(substituted or unsubstituted alkyl), -L5-(substituted or unsubstituted alkenyl), -L5-(substituted or unsubstituted heteroaryl), or -L5-(substituted or unsubstituted carbocyclic aryl), wherein L5 is —NHC(O)O, —NHC(O), —C(O)NH, —C(O)O, or —OC(O);
• or G is W-G1, where W is a substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl and G1 is H, —CO2H, tetrazolyl, —NHS(═O)2R8, S(═O)2N(R9), OH, —OR8, —C(═O)CF3, —C(O)NHS(═O)2R8, —S(═O)2NHC(O)R8, CN, N(R9)2, —C(═NR10)N(R9)2—NR9C(═NR10)N(R9)2, —NR9C(═CHR10)N(R9)2, —CO2R8, —CONH2, —CONHR8, or —CON(R8)2;
• each R8 is independently selected from substituted or unsubstituted lower alkyl, substituted or unsubstituted lower cycloalkyl;
• each R9 is independently selected from H, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower cycloalkyl or two R9 groups can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring;
• or R8 and R9 can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring and
• each R10 is independently selected from H, —S(═O)2R8, —S(═O)2NH2, —C(O)R8, —CN, —NO2, heteroaryl, or heteroalkyl;
• R11 is L7-G, L7-(substituted or unsubstituted cycloalkyl)-G, L7-(substituted or unsubstituted cycloalkenyl)-G, L7-(substituted or unsubstituted heteroaryl)-G, or L7-(substituted or unsubstituted carbocyclic aryl)-G, L7-(substituted or unsubstituted heterocycloalkyl)-G, where L7 is a bond, —C(O), —C(O)NH, (substituted or unsubstituted C1-C6 alkyl), or (substituted or unsubstituted C2-C6 alkenyl);
• or pharmaceutically acceptable salt thereof.